Humacyte Competitors
| HUMA Stock | USD 1.19 0.25 26.60% |
Humacyte vs Lipocine Correlation
Excellent diversification
The correlation between Humacyte and LPCN is -0.7 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Humacyte and LPCN in the same portfolio, assuming nothing else is changed.
Moving together with Humacyte Stock
Moving against Humacyte Stock
| 0.71 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.65 | ENGN | enGene Holdings Common | PairCorr |
| 0.62 | DSGN | Design Therapeutics | PairCorr |
| 0.5 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.41 | 63E | ONWARD MEDICAL BV | PairCorr |
Humacyte Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Humacyte and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Humacyte and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Humacyte does not affect the price movement of the other competitor.
| 0.85 | -0.26 | 0.74 | -0.87 | GOVX | ||
| 0.85 | -0.1 | 0.64 | -0.73 | BLRX | ||
| -0.26 | -0.1 | 0.2 | 0.4 | THAR | ||
| 0.74 | 0.64 | 0.2 | -0.57 | AIMD | ||
| -0.87 | -0.73 | 0.4 | -0.57 | LPCN | ||
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Humacyte Stock performing well and Humacyte Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Humacyte's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | 5.33 | (2.41) | 0.00 | (0.83) | 0.00 | 9.38 | 42.89 | |||
| BLRX | 2.59 | (0.27) | 0.00 | (0.19) | 0.00 | 5.20 | 13.04 | |||
| THAR | 5.48 | 0.50 | 0.08 | 0.40 | 5.92 | 11.55 | 40.06 | |||
| AIMD | 4.50 | (0.89) | 0.00 | (0.22) | 0.00 | 12.30 | 38.73 | |||
| LPCN | 5.03 | 2.00 | 0.39 | (14.40) | 3.32 | 15.95 | 33.09 |
Cross Equities Net Income Analysis
Compare Humacyte and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | 36.7 M | (2.3 M) | (2.1 M) | (2.3 M) | (2.7 M) | (2.7 M) | (3.3 M) | (2.2 M) | (2.6 M) | (2.4 M) | (2.9 M) | (18.5 M) | (14 M) | (26 M) | (25 M) | (22.5 M) | (21.4 M) |
| BLRX | (32.1 M) | (13.2 M) | (20.4 M) | (17.6 M) | (10.2 M) | (14.4 M) | (15.8 M) | (24.4 M) | (23 M) | (25.4 M) | (30 M) | (27.1 M) | (25 M) | (60.6 M) | (9.2 M) | (8.3 M) | (8.7 M) |
| THAR | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (2.4 M) | (2.2 M) | (8.5 M) | (9.3 M) | (12.2 M) | (11 M) | (10.4 M) |
| AIMD | (300 K) | (1.3 M) | (650.8 K) | (622.6 K) | (622.6 K) | (521.9 K) | (670 K) | (617.4 K) | (1.3 M) | (1.6 M) | (1.5 M) | (3.9 M) | (14 M) | (13.8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| LPCN | (5.2 K) | (5.2 K) | (76.7 K) | (10.6 M) | (20.4 M) | (18.2 M) | (19 M) | (21 M) | (11.7 M) | (13 M) | (21 M) | (634.4 K) | (10.8 M) | (16.4 M) | 8.4 K | 7.5 K | 7.9 K |
Humacyte and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Humacyte financial statement analysis. It represents the amount of money remaining after all of Humacyte operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Humacyte Competitive Analysis
The better you understand Humacyte competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Humacyte's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Humacyte's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Humacyte Competition Performance Charts
Five steps to successful analysis of Humacyte Competition
Humacyte's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Humacyte in relation to its competition. Humacyte's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Humacyte in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Humacyte's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Humacyte, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Humacyte position
In addition to having Humacyte in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cash Cows Thematic Idea Now
Cash Cows
Entities with stable and reliable earnings or profits, which allows them to pay consistent dividends to their shareholders. The Cash Cows theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cash Cows Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Humacyte Correlation with its peers. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. Market participants price Humacyte higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Humacyte assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.27) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Humacyte's market price often diverges from its book value, the accounting figure shown on Humacyte's balance sheet. Smart investors calculate Humacyte's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Humacyte's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.